Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TACR1 | P25103 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5185558 | 0.84 | MMP2 (0.40) | MMP2SLC6A4SLC6A3SLC6A2ALDH1A1 | |
| SCHEMBL5185566 | 0.84 | MMP2 (0.40) | MMP2SLC6A4SLC6A3SLC6A2ALDH1A1 | |
| SCHEMBL5185569 | 0.84 | MMP2 (0.40) | MMP2SLC6A4SLC6A3SLC6A2ALDH1A1 | |
| SCHEMBL5260323 | 0.83 | ACE (0.42) | POLB | |
| SCHEMBL5187913 | 0.79 | MMP2 (0.36) | MMP2SLC6A4SLC6A3SLC6A2ALDH1A1 | |
| SCHEMBL5185521 | 0.78 | HHAT (0.36) | MMP2POLB | |
| SCHEMBL4147781 | 0.78 | KEAP1 (0.41) | ALDH1A1POLB | |
| SCHEMBL5187275 | 0.77 | GPR183 (0.39) | MMP2ALDH1A1TACR1POLB | |
| SCHEMBL4147803 | 0.75 | MMP2 (0.32) | MMP2SLC6A4SLC6A3SLC6A2TACR1 | |
| SCHEMBL5185361 | 0.75 | CPB1 (0.49) | ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7288549-B2 | Heterocyclic compounds, method for preparing same and use thereof as medicines, in particular as antibacterial agents | AVENTIS PHARMA S.A. (FR) | 2007-10-30 | — | — | US | disclosed |
| US-20050245505-A1 | Novel heterocyclic compounds, method for preparing same and use thereof as medicines, in particular as antibacterial agents | ENTASIS THERAPEUTICS LIMITED (GB) | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245505-A1 | Novel heterocyclic compounds, method for preparing same and use thereof as medicines, in particular as antibacterial agents | FDPS, MRPL21, DHPS | MMP2 3974/4885SLC6A4 4171/4885SLC6A3 4061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.